Last update 18 Oct 2025

GD2-SADA:177Lu-DOTA Complex

Overview

Basic Info

Drug Type
Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals
Synonyms
GD2-SADA-177Lu-Proteus
Target
GD2
Action
modulators
Mechanism
GD2 modulators(Disialoganglioside GD2 modulators)
Therapeutic Areas
NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [1]
Active Indication
High Risk NeuroblastomaMelanomaMetastatic Solid Tumor+ [2]
Inactive Indication-
Originator Organization
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
Active Organization
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with GD2-SADA:177Lu-DOTA Complex
NCT05130255
/ RecruitingPhase 1
Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma
100 Clinical Results associated with GD2-SADA:177Lu-DOTA Complex
Login to view more data
100 Translational Medicine associated with GD2-SADA:177Lu-DOTA Complex
Login to view more data
100 Patents (Medical) associated with GD2-SADA:177Lu-DOTA Complex
Login to view more data
100 Deals associated with GD2-SADA:177Lu-DOTA Complex
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk NeuroblastomaPhase 1
United States
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
17 Nov 2022
MelanomaPhase 1
United States
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
17 Nov 2022
Metastatic Solid TumorPhase 1
United States
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
17 Nov 2022
SarcomaPhase 1
United States
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
17 Nov 2022
Small Cell Lung CancerPhase 1
United States
Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.
17 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free